Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

Samsung Bioepis biosimilar to Roche’s Herceptin wins FDA nod

Written by: | no-reply@reuters.com | Dated: Friday, January 18th, 2019

 

(Reuters) – The U.S. Food and Drug Administration said on Friday it had approved a biosimilar to Roche Holding AG’s blockbuster breast cancer treatment, Herceptin.

The biosimilar, Ontruzant, is sold by Merck Sharp & Dohme Corp, a unit of Merck & Co Inc, and is developed by Samsung Bioepis Co Ltd, which is a joint venture between Samsung BioLogics and Biogen Inc.

The approval here comes just a few weeks after the health regulator gave Celltrion Inc’s Herzuma – another biosimilar to Herceptin – its nod to market it commercially.

Herceptin, which generated sales of 7.01 billion Swiss francs in 2017, is one of the world’s most successful antibody drugs and has been a mainstay of Roche profits for many years.

Herceptin and other complex medicines called biologics are made from living cells, making them difficult to copy with precision. Their similar versions are called biosimilars, instead of generics.

The FDA had declined to approve Pfizer’s biosimilar of Herceptin in April.

 

Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Maju Samuel

 

Reuters source:

https://www.reuters.com/article/us-merck-co-fda-samsung-bioepis/samsung-bioepis-biosimilar-to-roches-herceptin-wins-fda-nod-idUSKCN1PC2I9

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom